Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Novel ZetaMet™ Technology Discovered for Metastatic Bone Cancers
Zetagen Therapeutics, discovered novel ZetaMet™ technology for the treatment of metastatic bone cancers. This technology is the first to suspend cancer inhibit pain, and regenerate bone. ZetaMet™ technology was earlier known as ZetaFuse. It is a synthetic, small-molecule, inductive biologic technology introduced to target and resolve metastatic
Breakthrough Biology-Guided Radiotherapy* (BgRT) Discovered for the Treatment of Lung Tumors
RefleXion Medical, Inc discovered breakthrough biology-guided radiotherapy* (BgRT)for the treatment of lung cancer. Biology-guided radiotherapy(BgRT), the first and only technology has the ability to detect and treat the circulating tumours producing active emissions from each tumour.
Pear Therapeutics Developed reSET-A™ PDT Product Candidate for Alcohol Use Disorder (AUD)
Pear therapeutics developed new reSET-A™ PDT product candidate for the treatment of alcohol use disorder (AUD) PDTsare new therapeutic class designed with software to directly treat disease. Similar to traditional medicines, PDT’s are developed and tested
Susvimo™, Breakthrough Therapy Discovered for Wet Age-Related Macular Degeneration (nAMD)
Roche discovered breakthrough therapy Susvimo™ (ranibizumab injection) for the treatment of people with neovascular or ‘wet’ age-related macular degeneration (nAMD). Susvimoearlier known as port delivery system with ranibizumab is the first and only alternative treatment in 15 years which provides standard-of-care
Novel NonInvasive Sonic Beam Device Developed for Non-Invasive Liver Treatment
HistoSonics developed novel sonic beam therapy for the destruction of targeted liver tissue. The new targeted liver therapy helps in providing timely access to non-invasive liver treatment and destructs targeted liver tissue. This is the first automated external beam therapy which makes use of acoustic energy
New Exo-PDAC Assay Discovered for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC)
Biological Dynamics, Inc discovered new Exo-PDAC, liquid biopsy assay for the early detection of pancreatic ductal adenocarcinoma (PDAC) in high-risk adults. Globally, pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal forms of cancer.
Novel Repotrectinib Therapeutic Option Discovered for Advanced Solid Tumors
Turning Point Therapeutics, Inc discovered novel repotrectinib, a leading drug candidate for the treatment of patients with advanced solid tumors having an NTRK gene fusion. Repotrectinib is a therapeutic option for patients who have shown progress with 1 or 2 prior TRK TKIs after treatment, with or without prior chemotherapy
SKYTROFA® (Lonapegsomatropin-tcgd), The First Therapy Discovered for Pediatric Growth Hormone Deficiency
Acendis Pharma discovered SKYTROFA (lonapegsomatropin-tcgd) for the treatment of pediatric growth hormone deficiency. It is the only once-weekly treatment applicable for patients with one year of age and older weighing at least 11.5kg having lack of growth due to insufficient secretion of endogenous
New Simoa® phospho-Tau 181 (pTau-181) Blood Test Discovered for Alzheimer’s Disease
Quanterix Corporation discovers new Blood-Based pTau-181 Assay for Alzheimer’s Disease. The Simoa® phospho-Tau 181 (pTau-181) blood test will be used for diagnostic evaluation of Alzheimer’s Disease (AD). With the use of HD-X immunoassay system, the pTau-181 concentration in human serum
Genentech Developed Breakthrough Therapy Gantenerumab for Alzheimer’s Disease
Genentech developed a breakthrough therapy for the treatment of patients living with early Alzheimer's disease (AD). This will be the first medicine to treat Alzheimer’s disease at-home administration. Gantenerumab is the first investigational IgG1 antibody designed with late-stage trials for the treatment of AD
